国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2008年
5期
317-319
,共3页
癌,非小细胞肺%药物疗法,联合%放射疗法
癌,非小細胞肺%藥物療法,聯閤%放射療法
암,비소세포폐%약물요법,연합%방사요법
Carcinoma,non-small cell lung%Drug therapy,combination%Radiotherapy
目的 比较放化疗联合治疗与单纯化疗对局部晚期非小细胞肺癌(NSCLC)的临床疗效及安全性.方法 65例不能手术的NSCLC患者,分为单纯化疗组(A组)30例、放化疗联合组(B组)35例,A组给予紫杉醇联合顺铂方案化疗两周期,B组同A组并给予同步放疗方案.对比两组疗效及安全性.结果 A组治疗有效率、1年生存率分别为36.7%、30.0%,B组分别为65.7%、54.3%,B组较A组明显提高(X2值分别为10.581和9.339,P<0.05).患者治疗后主要不良反应为骨髓抑制及肝功能异常;A组白细胞减少、血小板减少和肝功能异常发生率分别为33.3%、3.3%和56.7%,B组则分别为36.6%、10.0%和60.0%,两组相比均无显著性差异(X2值分别为2.011,0.007,2.206,P0.05).结论 局部晚期NSCLC放化疗联合治疗优于单纯化疗,不良反应能耐受.
目的 比較放化療聯閤治療與單純化療對跼部晚期非小細胞肺癌(NSCLC)的臨床療效及安全性.方法 65例不能手術的NSCLC患者,分為單純化療組(A組)30例、放化療聯閤組(B組)35例,A組給予紫杉醇聯閤順鉑方案化療兩週期,B組同A組併給予同步放療方案.對比兩組療效及安全性.結果 A組治療有效率、1年生存率分彆為36.7%、30.0%,B組分彆為65.7%、54.3%,B組較A組明顯提高(X2值分彆為10.581和9.339,P<0.05).患者治療後主要不良反應為骨髓抑製及肝功能異常;A組白細胞減少、血小闆減少和肝功能異常髮生率分彆為33.3%、3.3%和56.7%,B組則分彆為36.6%、10.0%和60.0%,兩組相比均無顯著性差異(X2值分彆為2.011,0.007,2.206,P0.05).結論 跼部晚期NSCLC放化療聯閤治療優于單純化療,不良反應能耐受.
목적 비교방화료연합치료여단순화료대국부만기비소세포폐암(NSCLC)적림상료효급안전성.방법 65례불능수술적NSCLC환자,분위단순화료조(A조)30례、방화료연합조(B조)35례,A조급여자삼순연합순박방안화료량주기,B조동A조병급여동보방료방안.대비량조료효급안전성.결과 A조치료유효솔、1년생존솔분별위36.7%、30.0%,B조분별위65.7%、54.3%,B조교A조명현제고(X2치분별위10.581화9.339,P<0.05).환자치료후주요불량반응위골수억제급간공능이상;A조백세포감소、혈소판감소화간공능이상발생솔분별위33.3%、3.3%화56.7%,B조칙분별위36.6%、10.0%화60.0%,량조상비균무현저성차이(X2치분별위2.011,0.007,2.206,P0.05).결론 국부만기NSCLC방화료연합치료우우단순화료,불량반응능내수.
Objective To compare the efficacy and adverse effects of radiotherapy currently combined with different chemotherapy for local advanced non-small cell lung cancer (NSCLC). Methods Sixty-five patients with NSCLC were divided into two groups. Group A was given taxol and cisplatin, and group B was given taxol and cisplatin combined with radiotherapy. The two groups were compared on the efficacy and safety. Results The total response (CR+PR) were 36.7% (group A) , 65.7% (group B),X2=10.581, P<0.05. The 1 year survival rates of group A were 30.0% and 54.3% of group B,X2=9.339, P<0.05. The adverse effects showed no significant difference (X2 value was 2.011, 0.007, 2.206 respectively, P0.05). Conclusion The radiotherapy concurrently combined with taxol and cisplatin chemotherapy for patients with NSCLC could be more effectively, and the patients could tolerate the side effects, this therapy method was secure and receivable.
